Immunohematology Market Size By Product (Analyzers, Reagents), By Technology (Biochips, Gel Cards, Microplates, PCR, Erythrocyte-magnetized Technology), By End-use (Hospitals, Diagnostic Laboratories, Blood Banks), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Jul 2021  |  Report ID: GMI1652  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 150   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Immunohematology Market size exceeded USD 2.3 billion in 2020 and is predicted to grow at 4% CAGR between 2021 and 2027. Market growth is attributed to the rising awareness surrounding blood donation. Several private and public entities as well as NGOs are noted to organize awareness campaigns for importance of blood donation as well as safe blood and blood products. Also, immunohematology technologies enable the detection of blood associated diseases and infections, thus fundamentally transforming the market space.
 

Immunohematology Market Overview

Get more details on this report - Request Free Sample PDF
 

The COVID-19 pandemic has disrupted all healthcare services including blood transfusion, storage as well as similar blood component services. At the onset of coronavirus, the research fraternity stated that transmission of COVID-19 infection via blood transfusion is only theorical and highly minimal. It is also noted that owing to the pandemic, governments as well as healthcare associations have implemented various regulations and guidelines to limit the spread of infection among healthcare practitioners.
 

While elective surgeries and non-urgent clinical interventions were deferred as a measure to optimise healthcare facilities for the treatment of COVID-19 patients, the demand for blood also plummeted. On the upside, the U.S. Food and Drug Administration (FDA) sanctioned emergency authorization of convalescent plasma therapy for the treatment of COVID-19 illness. The blood from recovered patients is studied to contain plasma and antibodies which boosts the infected patients’ immune system leading to a speedy recovery. With signs of hesitation being reported from several developing and under-developed countries, the blood transfusion services reported a sluggish growth and the market expanded in tandem with it. However, as consumers gain clarity surrounding plasma therapy and blood donation services, the market is anticipated to gain traction in the coming years.
 

Increasing prevalence of hematological disorders will spur the immunohematology market expansion

Hematological disease is a disorder associated with the blood and blood forming organs. It includes sickle cell anemia, thalassemia, lymphoma, leukemia, hemophilia, among others. For instance, according to the World Health Organization, approximately 4,74,519 number of leukemia new cases reported in the year 2020 and more than 3,11,594 deaths occurred due to leukemia in 2020. The increasing prevalence of leukemia around the world is one of the prime factors fostering the industry growth. Additionally, activities such as healthcare infrastructure upgradation, favorable government initiatives as well as increasing R&D expenses in the diagnosis and treatment of various hematological disorders are expected to have an optimistic impact on the industry.
 

High cost of hematology devices and software may restrict the market progression

Technological advancements in the immunohematology have led to the automation of devices, software up-gradation, high volume sample output, improved patient data management, alongside increased storage capabilities. The prices are also noted to have surged in tandem with technological advancements limiting the growth potential of the industry. Small and medium-volume laboratories use either basic machines or manual methods to perform hematology tests. An average advanced immunohematology analyzer with software could cost between USD 85,000 to USD 140,000 in the market. The high price associated with immunohematology analyzer may hinder the industry expansion over the forecast timeframe.
 

Reagents segment is slated to showcase significant growth

The reagents segment in the immunohematology market was valued at USD 1.5 billion in 2020. Reagents are primarily used in the immunohematology to analyze the ABO system, determination of group and Rh phenotype, infrequent groups, identification of infrequent antibodies, human antiglobulin, and others. As healthcare providers seek to maximize their output volume of results, the requirement of reagents also increases. Further, the rapid market demand for reagents segment can be attributed to the increasing demand of haematology tests, rising prevalence of hematological disorders as well as increasing blood donation.
 

PCR segment will observe exponential demand

Immunohematology Market Size

Get more details on this report - Request Free Sample PDF
 

The polymerase chain reaction (PCR) segment accounted for USD 857.9 million in 2020. Through PCR, multiple copies of genetic material (DNA or RNA) are generated to detect the viral load. The DNA based methods are essential for immunohematology typing. Further, the PCR segment is driven by the rising number of serological tests and increase in the prevalence of hematological disorders will fuel the industry progression.
 

Rise in the healthcare infrastructure will augment the market revenue

The hospital segment dominated more than 54.3% of the market share in 2020. The growing number of surgical procedures in hospitals has led to an increased demand for blood transfusion, thereby increasing the number of immunohematology tests, further stimulating the market value. Furthermore, automation of immunohematology devices leads to faster results with minimal errors, the development of public and private healthcare settings worldwide will further increase the industry size.
 

Increasing prevalence of leukemia in North America will impel the industry demand

Global Immunohematology Market

Get more details on this report - Request Free Sample PDF
 

North America immunohematology market is projected to witness 3.7% growth rate through 2027 on account of the high prevalence of leukemia in the North American region. According to the Leukemia & Lymphoma Society (LLS), approximately 376,508 people are living with leukemia in the U.S., and in 2020, 60,530 new cases were reported. Moreover, the availability of well-established healthcare infrastructure and ongoing clinical trials for the treatment of leukemia in the U.S. will propel the industry of immunohematology.
 

Growth strategies of market players are focused on increasing the customer base

A few key companies functioning in the market are Beckman Coulter, Thermo Fisher Scientific, Hologic, Abbott, Roche Diagnostics, Siemens Healthcare GmbH, Immucor, BD (Becton Dickinson), MTC Invitro, Antisel, Grifols, Ortho Clinical Diagnostics, Bio-Rad Laboratories. These market leaders are focusing on several strategies such as acquisitions, partnerships, new product launches, mergers and collaborations to increase their customer base and revenue share in the market.
 

Recent industry developments:

  • In March 2021, Roche announced a merger with GenMark Diagnostics to expand their molecular diagnostic tests. This strategy will benefit the company in expanding their product portfolio and to achieve larger market growth
     
  • In January 2021, Thermo Fisher Scientific Inc acquired Mesa Biotech, Inc. to boost their molecular diagnostic segment. This strategy will benefit the company to acquire larger market share in the PCR-based rapid point-of-care testing platform.
     

The immunohematology market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Product

  • Analyzers
  • Reagents

Market, By Technology

  • Biochips
  • Gel cards
  • Microplates
  • PCR
  • Erythrocyte-magnetized technology

Market, By End-use

  • Hospitals
  • Diagnostic laboratories
  • Blood banks

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Russia
    • Poland
    • Czech Republic
    • Hungary
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • South Africa 

 

Frequently Asked Questions (FAQ) :

The market size surpassed USD 2.4 billion in 2020 and will grow at a CAGR of 4% from 2021 to 2027.
Reagents recorded a revenue of over USD 1.5 billion in 2020 and will grow owing to their wide range of uses including the determination of group and Rh phenotype, analysis of the ABO system, and the identification of infrequent antibodies.
Polymerase chain reaction (PCR) registered a revenue of USD 857.9 million in 2020 and will depict appreciable growth driven by the increasing number of serological tests and the rising prevalence of hematological disorders.
The North America market will grow at a rate of 3.7% between 2021 and 2027 propelled by the high prevalence of leukemia in the region.

Premium Report Details

  • Published Date: Jul 2021
  • Pages: 150
  • Tables: 177
  • Charts / Figures: 17
  • Companies covered: 13
  • Countries covered: 17

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X